[Introduction] Some previous studies have reported favorable outcome of paclitaxle-eluting(PES) over sirolimus-eluting stents(SES) in patients with diabetes. These observations have not been studied in patients with acute myocardial infarction (AMI). [Methods] In Korea AMI Registry (KAMIR), 3,894 patients underwent stenting with SESs (n=2,220) or PESs (n=1,674) for STEMI in 41 centers in Korea, from Nov 2005 to Jan 2008. With the use of propensity-score matching, we evaluated the clinical outcomes of diabetic subgroup (n=561) and compared them with the non-diabetic population (n=1,695). [Results] With median follow-up of 358 days, there was no significant difference between SES and PES in the rate of major adverse cardiac event (MACE) (SES vs PES; 11.7 vs 12.6%, p=0.62) or target vessel revascularization (TVR) (SES vs PES; 4.5 vs 4.7%, p=0.95) at 1-year in the matched diabetic AMI population. In the non-diabetic AMI population, however, SES was superior to PES in terms of MACE (5.6% vs 9.8%, p=0.007), mainly due to reduced TVR (1.9 vs 4.9%, p=0.003). In other words, the presence of diabetes significantly increased the risk of TVR only in the SES group (1.9 to 4.5%, p=0.03), but not in the PES group (4.9 to 4.7%, p=0.98). (Figure) [Conclusions] In diabetic AMI patients, there was no significant difference between SES and PES in terms of MACE and TVR, which was in contrast to the result of non-diabetic AMI patients who showed less TVR with SES than PES.